NCT02259725View on ClinicalTrials.gov

Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 16, 2016

Primary Completion Date

August 20, 2020

Study Completion Date

August 20, 2020

Conditions
GastrinomaGlucagonomaInsulinomaMetastatic Gastrointestinal Carcinoid TumorPancreatic Polypeptide TumorPulmonary Carcinoid TumorRecurrent Gastrointestinal Carcinoid TumorRecurrent Islet Cell CarcinomaSomatostatinoma
Interventions
DRUG

regorafenib

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (5)

85259

Mayo Clinic in Arizona, Scottsdale

90033

USC Norris Comprehensive Cancer Center, Los Angeles

92663

Hoag Memorial Hospital Presbyterian, Newport Beach

USC Norris Oncology Hematology-Newport Beach, Newport Beach

98109

Seattle Cancer Care Alliance, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Southern California

OTHER

NCT02259725 - Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter